Relative Contributions of Cardiorespiratory Fitness and Visceral Fat to Metabolic Syndrome in Patients with Diabetes Mellitus

2005 ◽  
Vol 3 (3) ◽  
pp. 213-220 ◽  
Author(s):  
Shuzo Kumagai ◽  
Yuko Kai ◽  
Mayumi Nagano ◽  
Buha Zou ◽  
Hiroyo Kishimoto ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Cardiorespiratory Fitness ◽  
Visceral Fat ◽  
Patients With Diabetes

scholarly journals Electroneurographic parameters in patients with metabolic syndrome

2014 ◽  
Vol 4 (1) ◽  
pp. 45-49
Author(s):  
Suljo Kunić ◽  
Emir Tupković ◽  
Mediha Nišić ◽  
Semiha Salihović
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Glycemic Control ◽  
Action Potential ◽  
Median Nerve ◽  
Ulnar Nerve ◽  
Sensory Nerve ◽  
Group I ◽  
Patients With Diabetes ◽  
Group Ii

Introduction: The aim of this study was to measure electroneurographic (ENG) parameters of the median and ulnar nerve in patients with metabolic syndrome and to determine whether the large imbalance in glycemic control came to neuropathic changes to the template.Methods: The study included 100 patients with metabolic syndrome diagnosed according to the criteria of the National Cholesterol Education Program - Adult Treatment Panel III (NCEP-ATP III). The patients were divided into two groups. Group I – patients with normal glycemic control and Group II - patients with diabetes mellitus for up to five years. We measured sensory conductive velocity (SCV), the amplitude of sensory nerve action potential (SNAP), motor conductive velocity (MCV), terminal motor latency (TML) and compose muscle action potential after distal stimulation (CMAP-I) and after proximal stimulation (CMAP-II) for the ulnar and median nerve.Results: Sensory and motor parameters in Group II were amended to neuropathic pattern compared to Group I. There were significant differences in: SNAP amplitude for all tested nerves, SCV values for both left and right median and ulnar nerve; MCV and TML for left median nerve; MCV, TML and CMAP-I for right median nerve area; MCV and TML for left ulnar nerve; MCV, CMAP-I and CMAP-II for right ulnar nerve area.Conclusion: Patients with metabolic syndrome and diabetes mellitus duration of five years have the significant changes in sensory and motor peripheral nerves. Neuropathic changes are possible in patients with metabolic syndrome and normal glycemic control.

Relative Associations of Fitness and Visceral Fat to Metabolic Syndrome in Type 2 Diabetes Mellitus

2004 ◽  
Vol 36 (Supplement) ◽  
pp. S84???S85
Author(s):  
Yuko Kai ◽  
Buhao Zou ◽  
Mayumi Nagano ◽  
Haruka Sasaki ◽  
Shuzo Kumagai
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
Visceral Fat

Ultrasonographic visceral fat thickness in the first trimester can predict metabolic syndrome and gestational diabetes mellitus

Endocrine ◽  
2014 ◽  
Vol 47 (2) ◽  
pp. 478-484 ◽  
Author(s):  
Esra Bahar Gur ◽  
Ozlem Ince ◽  
Guluzar Arzu Turan ◽  
Muammer Karadeniz ◽  
Sumeyra Tatar ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Visceral Fat ◽  
First Trimester ◽  
Fat Thickness

Prevalence of the metabolic syndrome in patients with diabetes mellitus

2009 ◽  
Vol 178 (3) ◽  
pp. 309-313 ◽  
Author(s):  
F. AlSaraj ◽  
J. H. McDermott ◽  
T. Cawood ◽  
S. McAteer ◽  
M. Ali ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
The Metabolic Syndrome ◽  
Patients With Diabetes

scholarly journals 459 Evaluation of LDL-C reductions by siRNA treatment with inclisiran in patients with diabetes mellitus, metabolic syndrome or neither

2021 ◽  
Vol 23 (Supplement_G) ◽  
Author(s):  
R. Scott Wright ◽  
David Kallend ◽  
Kausik K Ray ◽  
Lawrence Leiter ◽  
Wolfgang Koenig ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Controlled Trial ◽  
Atherosclerotic Cardiovascular Disease ◽  
Double Blind ◽  
Sirna Treatment ◽  
Patients With Diabetes

Abstract Aims Patients with diabetes (DM) and metabolic syndrome (MS) have elevated risks for atherosclerotic cardiovascular disease (ASCVD). Aggressive LDL-C lowering reduces risks. Inclisiran, a new siRNA, lowers LDL-C and was evaluated in patients with Type 2 diabetes (DM), metabolic syndrome (MS) without DM or neither (N) in the ORION-10 trial. Methods ORION-10 was a double-blind, randomized, placebo controlled trial evaluating inclisiran in 1561 patients with ASCVD on maximally tolerated therapy for lowering LDL-C. 781 inclisiran (INC) participants and 780 placebo (P) patients received 1.5 mL SQ tx at Days 1, 90, then every 6 months until Day 540. We evaluated the time adjusted change in LDL-C from baseline after Days 90–540 in DM (n = 702), MS (n = 455) and N participants (n = 404). Results There were no differences in baseline demographics and background therapies between INC and P. Statins were utilized in 89.8% INC and 88.7% of P. High intensity statins were utilized in 67.2% of INC and 68.8% of P; ezetimibe in 10.2% of NC and 9.5% of P participants. INC reduced LDL-C by − 54.4% (−58.3, −50.6 95% CI) in DM, (P < 0.001), −58.6% (−62.3, −54.8), P < 0.001 in-MS and −56.0% (−60.2, −51.7), in N subjects P < 0.001 (see Figure). Conclusions Inclisiran potently and durably reduces LDL-C across patients with DM, MS and those with neither, demonstrating potent efficacy and durability across glycaemic categories. Inclisiran may also represent a potent LDL-C lowering treatment for those with DM and MS.

Sign in / Sign up

Export Citation Format

Share Document